{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:00:03Z","timestamp":1791907203003,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"ANRS\/MIE","award":["ECTZ 143960"],"award-info":[{"award-number":["ECTZ 143960"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-72449-1","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T10:02:14Z","timestamp":1729677734000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Atorvastatin and telmisartan do not reduce nasopharyngeal carriage of SARS-CoV-2 in mild or moderate COVID-19 in a phase IIb randomized controlled trial"],"prefix":"10.1038","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct04466241","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Fabrice","family":"Bonnet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adama","family":"Doumbia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Machault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic Nogbou","family":"Ello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantxika","family":"Bellecave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corine Bernice","family":"Akpovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baba Toumany","family":"Sidibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Kouam\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgard","family":"Adjogoua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireille","family":"Dosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Niangoran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Journot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge Paul","family":"Eholi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"72449_CR1","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"B Cao","year":"2020","unstructured":"Cao, B. et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N. Engl. J. Med. 382, 1787\u20131799. https:\/\/doi.org\/10.1056\/NEJMoa2001282 (2020).","journal-title":"N. Engl. J. Med."},{"key":"72449_CR2","doi-asserted-by":"publisher","unstructured":"Reis G, dos Santos Moreira Silva EA, Medeiros Silva DC, Thabane L, Singh G, Park JJH, et al. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19 The TOGETHER Randomized Clinical Trial. JAMA Network Open, https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.6468. (2021).","DOI":"10.1001\/jamanetworkopen.2021.6468"},{"key":"72449_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25489","author":"N Ford","year":"2020","unstructured":"Ford, N. et al. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: Initial assessment. JIAS https:\/\/doi.org\/10.1002\/jia2.25489 (2020).","journal-title":"JIAS"},{"key":"72449_CR4","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s11739-020-02364-6","volume":"15","author":"A Albini","year":"2020","unstructured":"Albini, A., Di Guardo, G., Noonan, D. M. & Lombardo, M. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies. Intern Emerg. Med. 15, 759\u2013766. https:\/\/doi.org\/10.1007\/s11739-020-02364-6 (2020).","journal-title":"Intern Emerg. Med."},{"key":"72449_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.820131","author":"L Teixeira","year":"2022","unstructured":"Teixeira, L. et al. Simvastatin downregulates the SARS-CoV-2-induced inflammatory response and impairs viral infection through disruption of lipid rafts. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.820131 (2022).","journal-title":"Front. Immunol."},{"key":"72449_CR6","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00398-20","author":"DS Fedson","year":"2020","unstructured":"Fedson, D. S., Opal, S. M. & Rordam, O. M. Hiding in plain sight: an approach to treating patients with severe COVID-19 infection. Mbio https:\/\/doi.org\/10.1128\/mBio.00398-20 (2020).","journal-title":"Mbio"},{"key":"72449_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.amjcard.2020.08.004","volume":"134","author":"CS Kow","year":"2020","unstructured":"Kow, C. S. & Hasan, S. S. Meta-analysis of effect of statins in patients with COVID-19. Am. J. Cardiol. 134, 153\u2013155. https:\/\/doi.org\/10.1016\/j.amjcard.2020.08.004 (2020).","journal-title":"Am. J. Cardiol."},{"key":"72449_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-02534-2","author":"L Shen","year":"2021","unstructured":"Shen, L. et al. Statin use and in-hospital mortality in patients with COVID-19 and coronary heart disease. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-021-02534-2 (2021).","journal-title":"Sci. Rep."},{"key":"72449_CR9","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.amjmed.2022.02.018","volume":"135","author":"W Li","year":"2022","unstructured":"Li, W. et al. Statin use in hospitalized patients with COVID-19: A comprehensive analysis of the New York City public hospital system. Am. J. Med. 135, 897\u2013905. https:\/\/doi.org\/10.1016\/j.amjmed.2022.02.018 (2022).","journal-title":"Am. J. Med."},{"key":"72449_CR10","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1136\/postgradmedj-2020-139172","volume":"98","author":"R Pal","year":"2021","unstructured":"Pal, R., Banerjee, M., Yadav, U. & Bhattacharjee, S. Statin use and clinical outcomes in patients with COVID-19: An updated systematic review and meta-analysis. Postgrad. Med. J. 98, 354\u2013359. https:\/\/doi.org\/10.1136\/postgradmedj-2020-139172 (2021).","journal-title":"Postgrad. Med. J."},{"key":"72449_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2024.06.002.)","author":"CF de Mesquita","year":"2024","unstructured":"de Mesquita, C. F. et al. Adjunctive statin therapy in patients with COVID-19: A systematic review analysis and meta-analysis of randomized controlled trials. Am. J. Med. https:\/\/doi.org\/10.1016\/j.amjmed.2024.06.002.) (2024).","journal-title":"Am. J. Med."},{"key":"72449_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-076195","author":"Y Rong","year":"2023","unstructured":"Rong, Y. et al. Association of antecedent statin use on 30-day, 60-day and 90-day mortality among Mississippi Medicaid beneficiaries diagnosed with COVID-19. BMJ Open https:\/\/doi.org\/10.1136\/bmjopen-2023-076195 (2023).","journal-title":"BMJ Open"},{"key":"72449_CR13","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jjcc.2021.12.012","volume":"79","author":"T Kuno","year":"2022","unstructured":"Kuno, T., So, M., Iwagami, M., Takahashi, M. & Egorova, N. N. The association of statins use with survival of patients with COVID-19. J. Cardiol. 79, 494\u2013500. https:\/\/doi.org\/10.1016\/j.jjcc.2021.12.012 (2022).","journal-title":"J. Cardiol."},{"key":"72449_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-058363","author":"PL Wander","year":"2022","unstructured":"Wander, P. L. et al. Associations of statin use with 30-day adverse outcomes among 4 801 406 US Veterans with and without SARS-CoV-2: An observational cohort study. BMJ Open https:\/\/doi.org\/10.1136\/bmjopen-2021-058363 (2022).","journal-title":"BMJ Open"},{"key":"72449_CR15","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1007\/s11606-022-07701-3","volume":"37","author":"CM Hunt","year":"2022","unstructured":"Hunt, C. M. et al. Medications associated with lower mortality in a SARS-CoV-2 positive cohort of 26,508 veterans. J. Gen. Intern. Med. 37, 4144\u20134152. https:\/\/doi.org\/10.1007\/s11606-022-07701-3 (2022).","journal-title":"J. Gen. Intern. Med."},{"key":"72449_CR16","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1097\/CCM.0000000000005589","volume":"50","author":"GLY Rocheleau","year":"2022","unstructured":"Rocheleau, G. L. Y. et al. Renin-angiotensin system pathway therapeutics associated with improved outcomes in males hospitalized with COVID-19. Crit. Care Med. 50, 1306\u20131317. https:\/\/doi.org\/10.1097\/CCM.0000000000005589 (2022).","journal-title":"Crit. Care Med."},{"key":"72449_CR17","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1093\/ajh\/hpac001","volume":"35","author":"J Yin","year":"2022","unstructured":"Yin, J., Wang, C., Song, X., Li, X. & Miao, M. Effects of renin-angiotensin system inhibitors on mortality and disease severity of COVID-19 patients: A meta-analysis of randomized controlled Trials. Am. J. Hypertens. 35, 462\u2013469. https:\/\/doi.org\/10.1093\/ajh\/hpac001 (2022).","journal-title":"Am. J. Hypertens."},{"key":"72449_CR18","doi-asserted-by":"publisher","unstructured":"Jeffery MM, Oliveira J E Silva L, Bellolio F, Garovic VD, Dempsey TM, et al. Association of outpatient use of renin-angiotensin-aldosterone system blockers on outcomes of acute respiratory illness during the COVID-19 pandemic: a cohort study. BMJ Open, https:\/\/doi.org\/10.1136\/bmjopen-2021-060305. (2022).","DOI":"10.1136\/bmjopen-2021-060305"},{"key":"72449_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08913-6","author":"Z Zhang","year":"2023","unstructured":"Zhang, Z. et al. Long-term oral ACEI\/ARB therapy is associated with disease severity in elderly COVID-19 omicron BA.2 patients with hypertension. BMC Infect. Dis. https:\/\/doi.org\/10.1186\/s12879-023-08913-6 (2023).","journal-title":"BMC Infect. Dis."},{"key":"72449_CR20","first-page":"156","volume":"23","author":"SJ Little","year":"2016","unstructured":"Little, S. J. Treatment of acute HIV infection and the potential role of acutely HIV-infected persons in cure studies. Top Antivir. Med. 23, 156\u2013160 (2016).","journal-title":"Top Antivir. Med."},{"key":"72449_CR21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910993","author":"S Mulangu","year":"2019","unstructured":"Mulangu, S. et al. A randomized, controlled trial of ebola virus disease therapeutics. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa1910993 (2019).","journal-title":"N. Engl. J. Med."},{"key":"72449_CR22","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1186\/s12879-022-07663-1","volume":"22","author":"D Bhavnani","year":"2022","unstructured":"Bhavnani, D. et al. SARS-CoV-2 viral load is associated with risk of transmission to household and community contacts. BMC Infect Dis. 22, 672. https:\/\/doi.org\/10.1186\/s12879-022-07663-1 (2022).","journal-title":"BMC Infect Dis."},{"key":"72449_CR23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1056\/NEJMoa1809866","volume":"381","author":"DV Havlir","year":"2019","unstructured":"Havlir, D. V. et al. HIV testing and treatment with the use of a community health approach in rural Africa. N. Engl. J. Med. 381, 219\u2013229. https:\/\/doi.org\/10.1056\/NEJMoa1809866 (2019).","journal-title":"N. Engl. J. Med."},{"key":"72449_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1443","author":"S Zheng","year":"2020","unstructured":"Zheng, S. et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. BMJ https:\/\/doi.org\/10.1136\/bmj.m1443 (2020).","journal-title":"BMJ"},{"key":"72449_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa153","author":"G Wang","year":"2020","unstructured":"Wang, G. et al. C-Reactive protein level may predict the risk of COVID-19 aggravation. Open Forum Infect Dis https:\/\/doi.org\/10.1093\/ofid\/ofaa153 (2020).","journal-title":"Open Forum Infect Dis"},{"key":"72449_CR26","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1186\/s12879-022-07570-5","volume":"202","author":"N Ghati","year":"2022","unstructured":"Ghati, N. et al. Statin and aspirin as adjuvant therapy in hospitalised patients with SARS-CoV-2 infection: A randomised clinical trial (RESIST trial). BMC Infect Dis. 202, 606. https:\/\/doi.org\/10.1186\/s12879-022-07570-5 (2022).","journal-title":"BMC Infect Dis."},{"key":"72449_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101242","author":"HG Gaitan-Duarte","year":"2022","unstructured":"Gaitan-Duarte, H. G. et al. Effectiveness of rosuvastatin plus colchicine, emtricitabine\/tenofovir and combinations thereof in hospitalized patients with COVID-19: A pragmatic, open-label randomized trial. E Clin. Med. https:\/\/doi.org\/10.1016\/j.eclinm.2021.101242 (2022).","journal-title":"E Clin. Med."},{"key":"72449_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068407","author":"INSPIRATION-S Investigators","year":"2022","unstructured":"INSPIRATION-S Investigators. Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial. BMJ https:\/\/doi.org\/10.1136\/bmj-2021-068407 (2022).","journal-title":"BMJ"},{"issue":"25","key":"72449_CR29","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1056\/NEJMoa2309995","volume":"389","author":"The REMAP-CAP Investigators","year":"2023","unstructured":"The REMAP-CAP Investigators. Simvastatin in critically Ill patients with Covid-19. N. Engl. J. Med. 389(25), 2341\u20132354. https:\/\/doi.org\/10.1056\/NEJMoa2309995 (2023).","journal-title":"N. Engl. J. Med."},{"key":"72449_CR30","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1097\/CCM.0b013e318225742c","volume":"39","author":"D Makris","year":"2011","unstructured":"Makris, D. et al. Effect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: Open-label, randomized study. Crit. Care Med. 39, 2440\u20132446 (2011).","journal-title":"Crit. Care Med."},{"key":"72449_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.280031","author":"L Papazian","year":"2013","unstructured":"Papazian, L. et al. Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: A randomized clinical trial. JAMA https:\/\/doi.org\/10.1001\/jama.2013.280031 (2013).","journal-title":"JAMA"},{"key":"72449_CR32","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.4049\/jimmunol.2000642","volume":"205","author":"R Franco","year":"2020","unstructured":"Franco, R. et al. SARS-CoV-2 as a factor to disbalance the reninangiotensin system: a suspect in the case of exacerbated IL-6 production. J. Immunol. 205, 1198. https:\/\/doi.org\/10.4049\/jimmunol.2000642 (2020).","journal-title":"J. Immunol."},{"key":"72449_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100962","author":"M Duarte","year":"2021","unstructured":"Duarte, M. et al. Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial. E Clin. Med. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100962 (2021).","journal-title":"E Clin. Med."},{"key":"72449_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-072175","author":"MJ Jardine","year":"2022","unstructured":"Jardine, M. J. et al. Angiotensin receptor blockers for the treatment of covid-19: Pragmatic, adaptive, multicentre, phase 3, randomised controlled trial. BMJ https:\/\/doi.org\/10.1136\/bmj-2022-072175 (2022).","journal-title":"BMJ"},{"key":"72449_CR35","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s11262-023-01984-2","volume":"59","author":"EA Anoh","year":"2023","unstructured":"Anoh, E. A. et al. Subregional origins of emerging SARS-CoV-2 variants during the second pandemic wave in C\u00f4te d\u2019Ivoire. Virus Genes 59, 370\u2013376. https:\/\/doi.org\/10.1007\/s11262-023-01984-2 (2023).","journal-title":"Virus Genes"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-72449-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-72449-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-72449-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T10:06:17Z","timestamp":1729677977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-72449-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["72449"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-72449-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"assertion":[{"value":"24 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Fabrice Bonnet has received consulting honoraria, research grants, or both from Gilead Sciences, MSD, and ViiV Healthcare, outside the submitted work. Other authors have nothing to disclose. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The trial was approved by the institutional national ethics committee (Comit\u00e9 National d\u2019Ethique de la Vie et de la Sant\u00e9 (CNEVS), July 27, 2020) and was conducted in accordance with the 1964 Helsinki Declaration and the French and Ivorian regulations on clinical trials. We obtained written informed consent from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"25028"}}